FLT3 and acute myeloid leukemia: Although generally associated with favorable prognosis, especially in the absence of FLT3-ITD, approximately 50% of NPM1-mutated AML patients receiving conventional treatment approaches, based on chemotherapy and HSCT procedures, still currently die due to disease relapse and progression [7,8,87].